Triple

T10790400
Position Surface form Disambiguated ID Type / Status
Subject White Oak, Maryland E254561 entity
Predicate isNearFederalFacility P22439 FINISHED
Object U.S. Food and Drug Administration Office of Pediatric Therapeutics
The U.S. Food and Drug Administration Office of Pediatric Therapeutics is an FDA office dedicated to ensuring that medical products are appropriately studied, labeled, and regulated for safe and effective use in children.
E886017 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: U.S. Food and Drug Administration Office of Pediatric Therapeutics | Statement: [White Oak, Maryland, isNearFederalFacility, U.S. Food and Drug Administration Office of Pediatric Therapeutics]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: U.S. Food and Drug Administration Office of Pediatric Therapeutics
Context triple: [White Oak, Maryland, isNearFederalFacility, U.S. Food and Drug Administration Office of Pediatric Therapeutics]
  • A. American Society for Clinical Pharmacology and Therapeutics
    The American Society for Clinical Pharmacology and Therapeutics is a professional organization dedicated to advancing the science and practice of clinical pharmacology and translational medicine to improve patient care.
  • B. Office of Orphan Products Development
    The Office of Orphan Products Development is a U.S. Food and Drug Administration office that promotes the development of drugs and other medical products for rare diseases and conditions.
  • C. Center for Drug Evaluation and Research
    The Center for Drug Evaluation and Research is the U.S. FDA division responsible for overseeing the safety, effectiveness, and quality of prescription and over-the-counter drugs.
  • D. Office of Pharmacy Affairs
    The Office of Pharmacy Affairs is a division within the U.S. Health Resources and Services Administration that oversees federal drug discount initiatives for safety-net healthcare providers.
  • E. Office of Pharmaceutical Quality
    The Office of Pharmaceutical Quality is a U.S. Food and Drug Administration office responsible for ensuring the quality, safety, and consistency of human drugs throughout their lifecycle.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: U.S. Food and Drug Administration Office of Pediatric Therapeutics
Triple: [White Oak, Maryland, isNearFederalFacility, U.S. Food and Drug Administration Office of Pediatric Therapeutics]
Generated description
The U.S. Food and Drug Administration Office of Pediatric Therapeutics is an FDA office dedicated to ensuring that medical products are appropriately studied, labeled, and regulated for safe and effective use in children.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07
Target entity: U.S. Food and Drug Administration Office of Pediatric Therapeutics
Target entity description: The U.S. Food and Drug Administration Office of Pediatric Therapeutics is an FDA office dedicated to ensuring that medical products are appropriately studied, labeled, and regulated for safe and effective use in children.
  • A. American Society for Clinical Pharmacology and Therapeutics
    The American Society for Clinical Pharmacology and Therapeutics is a professional organization dedicated to advancing the science and practice of clinical pharmacology and translational medicine to improve patient care.
  • B. Office of Orphan Products Development
    The Office of Orphan Products Development is a U.S. Food and Drug Administration office that promotes the development of drugs and other medical products for rare diseases and conditions.
  • C. Center for Drug Evaluation and Research
    The Center for Drug Evaluation and Research is the U.S. FDA division responsible for overseeing the safety, effectiveness, and quality of prescription and over-the-counter drugs.
  • D. Office of Pharmacy Affairs
    The Office of Pharmacy Affairs is a division within the U.S. Health Resources and Services Administration that oversees federal drug discount initiatives for safety-net healthcare providers.
  • E. Office of Pharmaceutical Quality
    The Office of Pharmaceutical Quality is a U.S. Food and Drug Administration office responsible for ensuring the quality, safety, and consistency of human drugs throughout their lifecycle.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69d6aa609f008190a294200aefcb7bd5 completed April 8, 2026, 7:20 p.m.
NER Named-entity recognition batch_69d732f5b8248190a633dc44ae620a3a completed April 9, 2026, 5:02 a.m.
NED1 Entity disambiguation (via context triple) batch_69de5637ec50819087f1a0372f89197d completed April 14, 2026, 2:59 p.m.
NEDg Description generation batch_69de5eadb9448190bdf69711394e2ab7 completed April 14, 2026, 3:35 p.m.
NED2 Entity disambiguation (via description) batch_69de607917808190922df6521d7bfb07 completed April 14, 2026, 3:42 p.m.
Created at: April 8, 2026, 9:17 p.m.